Recombinant Rat TNFRSF18 protein, His-tagged

• Cat.No.: TNFRSF18-332R
• Product Overview: Recombinant Rat TNFRSF18 protein (Gln20-Lys121), fused to His tag at C-terminus, was expressed in human 293 cells (HEK293).

Specification

• Description: Glucocorticoid-induced TNFR-related protein (GITR) is also known as Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), activation-inducible TNFR family receptor (AITR), CD antigen CD357, which is a member of the tumor necrosis factor receptor (TNF-R) superfamily. GITR is receptor for TNFSF18, which seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. GITR also mediated NF-kappa-B activation via the TRAF2/NIK pathway.
• Source: HEK293
• Species: Rat
• Tag: His
• Form: Lyophilized from 0.22 um filtered solution in PBS, pH7.4, 10% trehalose.
• Molecular Mass: The protein has a calculated MW of 12.1 kDa. The protein migrates as 21 kDa under reducing (R) condition (SDS-PAGE).
• Protein length: 102
• Endotoxin: Less than 1.0 EU per ug by the LAL method.
• Purity: >95% as determined by SDS-PAGE.
• Storage: For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
  Please avoid repeated freeze-thaw cycles.
  This product is stable after storage at:
  -20 centigrade to -70 centigrade for 12 months in lyophilized state;
  -70 centigrade for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: TNFRSF18
• Official Symbol: TNFRSF18
• Synonyms: TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18
• Gene ID: 500598
• mRNA Refseq: NM_001024349
• Protein Refseq: NP_001019520
• UniProt ID: Q5M835

Reviews

12/20/2021

This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

03/05/2020

Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

10/01/2017

The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

Q&As

What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment?

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment?

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies?

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes?

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies?

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.